Financhill
Back

Ionis Pharmaceuticals Quote, Financials, Valuation and Earnings

Tech insider: "Watch your mailbox"

Full story here.
Buy
70

IONS
Ionis Pharmaceuticals

Last Price:
48.65
Seasonality Move:
8.21%

7 Day Trial

ALL ACCESS PASS

$ 7

Unveiling AI's $2 Trillion Opportunity!

Grab your FREE guide before it's gone. Click here Now!

Ionis Pharmaceuticals Price Quote

$48.65
-0.04 (-1.66%)
(Updated: December 9, 2023 at 9:31 AM ET)

Ionis Pharmaceuticals Key Stats

Buy
70
Ionis Pharmaceuticals (IONS) is a Buy

Day range:
$48.51 - $49.46
52-week range:
$32.69 - $51.89
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
11.30
P/B ratio:
22.14%

Volume:
742K
Avg. volume:
1M
1-year change:
28.13%
Market cap:
$7B
Revenue:
$587.4M
EPS:
$-2.87

How Much Does Ionis Pharmaceuticals Make?

Is Ionis Pharmaceuticals Growing As A Company?

  • What Is Ionis Pharmaceuticals's Growth Rate Quarterly?
    Quarterly YoY revenue growth is -0.1%
  • What Is Ionis Pharmaceuticals's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Ionis Pharmaceuticals Stock Price Performance

What Is Ionis Pharmaceuticals 52-Week High & Low?

Ionis Pharmaceuticals Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Ionis Pharmaceuticals?

Is Ionis Pharmaceuticals Cash Flow Positive?

  • What Is IONS Cash Flow From Operations?
    Cash flow from operations (TTM) is -$540.6M
  • What Is Ionis Pharmaceuticals’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $552.3M
  • What Is Ionis Pharmaceuticals’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $24.7M

Ionis Pharmaceuticals Return On Invested Capital

  • Is Management Doing A Good Job?
    IONS return on invested capital is -23.83%
  • What Is Ionis Pharmaceuticals Return On Assets?
    ROA measures how assets are converting to revenues and is -14.89%
  • What Is IONS Return On Equity?
    ROE is a measure of profitability and is -85.39%

Ionis Pharmaceuticals Earnings Date & Stock Price

Ionis Pharmaceuticals Competitors

Ionis Pharmaceuticals Dividend Yield

Data Unavailable

Ionis Pharmaceuticals Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 4.77%
Revenue: -9.74% 5.58%

Analyst Recommendations

Buy Recommendations: 8
Hold Recommendations: 7
Sell Recommendations: 1
Price Target: 54.38
Upside from Last Price: 11.69%

Major Shareholders

  • How many IONS shares are owned by institutional investors?
    228.3M IONS shares are owned by institutional investors
  • How many IONS shares are owned by insiders?
    1.2M IONS shares are owned by insiders